Novartis AG (NYSE:NVS) is considered one of the best slow growth stocks to invest in, with TD Cowen reaffirming a Hold rating and $140 price target. Key growth drivers include existing medicines like Cosentyx and immunology foothold through Rhapsido and ianalumab. The company revised its mid-term sales target, aiming for a CAGR of 5-6% and margins above 40% by 2029. Novartis AG focuses on innovative medicines to improve lives and combat serious diseases.

Read more at Yahoo Finance: TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029